copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Products - GSK US Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations If you are a healthcare professional, you can access more product information on our GSKPro website In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center
us. gsk. com Trade marks are owned by or licensed to the GSK group of companies < p>\n<p>GSK plc Registered in England and Wales No 3888792 < p>\n<p>Registered office: 79 New Oxford Street, London
Vaccines | GSK US The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to smallpox vaccine production since 1882 Today, our vaccines continue to make an impact for society by tackling some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and
Purpose, strategy and culture - GSK US GSK is a company where outstanding people can thrive We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease
GSK’s 5-in-1 meningococcal vaccine PENMENVY receives positive . . . GSK’s MenB vaccine has received regulatory approval in over 55 countries, including the US, and is used in 18 national immunization programs worldwide for the prevention of IMD caused by Neisseria meningitidis serogroup B
GSK data at ASH show potential to redefine outcomes for people living . . . GSK plc (LSE NYSE: GSK) will present new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6 - 9), reinforcing its potential to redefine outcomes for patients with difficult-to-treat blood cancers
Exdensur (depemokimab) approved by US FDA for the . . . - us. gsk. com GSK plc (LSE NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older